TD Asset Management
AKTS

TD Asset Management’s Aktis Oncology AKTS Stock Holding History

TD Asset Management’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41M Buy
105,902
+4,940
+5% +$101K ﹤0.01% 882
2026
Q1 		$1.81M Buy
+100,962
New +$1.96M ﹤0.01% 989

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TD Asset Management's AKTS Position: Q2 2026 in Review

TD Asset Management increased its Aktis Oncology (AKTS) stake by 4.9% in Q2 2026, buying an estimated $101K and bringing the position to 105,902 shares worth $3.41M. The position accounts for ﹤0.01% of the portfolio, ranked #882.

TD Asset Management first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • TD Asset Management held 105,902 shares of Aktis Oncology worth $3.41M as of Q2 2026.
  • TD Asset Management bought 4,940 Aktis Oncology shares in Q2 2026, an estimated $101K.
  • Aktis Oncology made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #882 holding.
  • TD Asset Management first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.